

I hereby certify that this correspondence is  
being deposited with the United States Postal  
Service as first class mail in an envelope  
addressed to Assistant Commissioner for Patents,  
Washington, D.C. 20231, on  
March 4, 2003

Anita W. Magatti  
Registered Representative

  
Signature

March 4, 2003  
Date of Signature

RECEIVED  
MAR 17 2003  
TECH CENTER 1600/2900

PATENT  
CASE CN01180K1

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

-----X  
In re Application of: :  
Bernard R Neustadt et al :  
:   
For Patent For: Examiner: John M. Ford  
Adenosine A2a Receptor Antagonists :  
Art Unit: 1624  
Serial No.: 09/865,071 :  
Filing Date: May 24, 2001 :  
-----X

Assistant Commissioner for Patents  
Washington, D.C. 20231

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
**PURSUANT TO 37 C.F.R. 1.97(c) OR (d)**

Sir:

37 C.F.R. 1.97(c)

- 1.a. ☒ The information disclosure statement transmitted herewith is being filed after three months of the filing date of this national application or the date of entry of the national stage as set forth in § 1.491 in an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either:
- (1) a final action under § 1.113, or
  - (2) a notice of allowance under § 1.311, whichever occurs first.
- 1.b. ☐ This statement is accompanied by the certification set forth below. OR
- 1.c. ☒ Applicant(s) elect to pay the fee of \$180.00 for the submission of this information disclosure statement.

37 C.F.R. 1.97(d)

- 2.a. ☐ The information disclosure statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before, or simultaneously with, the payment of the issue fee.
- 2.b. ☐ This statement is accompanied by the certification set forth below. AND
- 2.c. ☐ Applicant(s) hereby petition for the consideration of the accompanying information disclosure statement. AND
- 2.d. ☐ The fee for this petition is \$130.00.

METHOD OF PAYMENT

- 3.a. ☒ Charge \$ 180.00 to Deposit Account No. 19-0365.
- 3.b. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0365.

CERTIFICATION

4. ☐ I, the person signing below, hereby certify
- ☐ that each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the statement, or
- ☐ that no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in § 1.56(c) more than three months prior to the filing of the statement.


\_\_\_\_\_  
Name

\_\_\_\_\_  
Signature

\_\_\_\_\_  
Date

SCHERING-PLOUGH CORPORATION  
Patent Department, K-6-1, 1990  
2000 Galloping Hill Road  
Kenilworth, New Jersey 07033-0530  
Date: March 4, 2003

Respectfully submitted,

  
Anita W. Magatti  
Attorney/Agent for Applicant(s)  
Registration No.: 29,825  
Telephone No.: (908) 298-5067

RECEIVED  
MAR 17 2003  
TECH CENTER 1600/2900



#6

PATENT  
CASE CN01180K1

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

-----X  
In re Application of: :  
Bernard R Neustadt et al :

For Patent For: :  
Adenosine A2a Receptor Antagonists :

Examiner: J. Ford

Art Unit: 1624

Serial No.: 09/865,071 :

Filing Date: May 24, 2001 :  
-----X

Schering-Plough Corporation  
Kenilworth, New Jersey 07033-0530

Assistant Commissioner for Patents  
Washington, D.C. 20231

RECEIVED  
MAR 17 2003  
TECH CENTER 1600/2900

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Sir:

This statement is made in compliance with 37 C.F.R. 1.56, 1.97 and 1.98. Applicants enclose a Form PTO-1449 (1 page) listing an additional publication known to applicants that may be relevant to this application. This Statement is being submitted after three months from filing the application and after an action on the merits has been received. A transmittal form authorizing payment of the necessary fee accompanies this statement.

Publication BL discloses substituted [1,2,4]triazolo[1,5-c]pyrimidines differing from the instantly claimed compounds in the 5-position substituent in the pyrimidine portion and in the substitution on the pyrazolo ring portion ("A" in the reference).

It is noted that four of the references cited in applicants original IDS – AL, AN, AR, and the US equivalent to AM - were cited in the International Search Report of corresponding application PCT application WO 01/92264.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C., 20231, on March 4, 2003

**Anita W. Magatti**

Registered Representative

  
Signature

3/4/03  
Date

03/14/2003 BABRAHA1 00000102 190365 09865071


01 FC:1806

180.00 CH

A copy of the newly cited publication is attached.

The examiner is respectfully requested to examine the publications,  
initial the form PTO-1449 and return a copy of the initialed form to applicants.

Respectfully submitted,



---

Anita W. Magatti  
Reg. No. 29,825  
Attorney for Applicants  
(908) 298-5067